Loading...
Loading...
Generating destination analysis
Unlock Full TMO Analysis
UpgradeMarket Cap
$200B
P/E
32
Revenue Growth
+4.0%
Gross Margin
N/A
ROE
N/A
Thermo Fisher Scientific is a mega-cap healthcare company listed on the NYSE, blending biotech and genomics initiatives alongside its core business operations. Life sciences tools giant providing instruments, reagents, and services to biotech. Valued at 32x trailing earnings with a $200B market capitalization, Thermo Fisher Scientific has delivered modest revenue growth with revenue moving +4% over the past year.
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
ARK Genomic Revolution ETF
ETF focused on companies advancing genomics, gene editing, and therapeutics.
DexCom Inc.
Continuous glucose monitoring leader expanding beyond diabetes management.
Alnylam Pharmaceuticals
RNA interference therapeutics leader with approved treatments for rare diseases.
Eli Lilly and Company
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.